<DOC>
	<DOCNO>NCT02579707</DOCNO>
	<brief_summary>This 2-part study . PART 1 open-label , randomize , food effect study AG-120 . Subjects enrol fed/fasted fasted/fed treatment sequence 2-period crossover design . PART 2 open-label study determine safety PK parameter single 1000-mg oral dose AG-120 .</brief_summary>
	<brief_title>Food Effect Study AG120 Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1. male female , age 18 55 year , inclusive 2. within body mass index ( BMI ) range 18 33 kg/m2 , inclusive 3. good health , determine absence clinically significant finding medical history , 12lead ECG , vital sign 4. fast clinical laboratory value within normal reference range test laboratory , unless deem clinically significant Investigator . ( Calcium , magnesium , potassium level within normal range ) 5. negative test select drug abuse cotinine Screening ( include alcohol ) Checkin Period 1 ( Parts 1 2 ) Period 2 ( Part 1 ) ( include alcohol via breathalyzer ) 6. negative hepatitis panel ( include hepatitis B surface antigen hepatitis C virus antibody ) negative human immunodeficiency virus ( HIV ) antibody screen 7. female subject reproductive potential must agree undergo medically supervised pregnancy test prior study drug administration . Pregnancy test perform Screening confirm negative Checkin 8. female reproductive potential must agree abstain sexual intercourse use 2 highly effective form contraception time give informed consent , study , 90 day follow last dose AG120 . 9. male must either sterile agree use 2 follow approve method contraception time give informed consent 90 day follow last dose administration . Subjects refrain sperm donation time give informed consent 90 day follow last dose administration 10. able comprehend willing sign Informed Consent Form ( ICF ) 1. history clinical manifestation metabolic , allergic , dermatological , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , neurological , psychiatric disorder ( determined Investigator ) 2. history significant hypersensitivity , intolerance , allergy drug compound , food , substance , unless approve Investigator 3. history stomach intestinal surgery resection would potentially alter absorption and/or excretion orally administer drug except appendectomy hernia repair allow 4. history presence abnormal ECG , , Investigator 's opinion , clinically significant . QTcF value must within range indicate inclusion criterion # 3 5. history alcoholism drug addiction within 2 year first dose administration , positive drug screen test reflect consumption illicit drug positive alcohol screen Checkin 6. use tobacco nicotinecontaining product ( include limit cigarette , ecigarettes , pipe , cigar , chew tobacco , nicotine patch , nicotine lozenge , nicotine gum ) within 6 month prior Screening Study Completion , positive cotinine screen Screening Checkin 7. unwilling refrain strenuous exercise 48 hour prior Checkin period confinement Clinical Research Unit otherwise maintain normal level physical activity throughout entire study ( ie , begin new exercise program participate unusually strenuous physical exertion ) 8. participation clinical trial investigational study drug administer within 5 halflives 30 day Screening , whichever longer 9. use hormonal oral , implantable , injectable , transdermal contraceptive time sign ICF ( female ) 90 day last dose administration 10. use prescription medications/products within 14 day prior initial Checkin Study Completion , unless deem acceptable Investigator 11. use overthecounter , nonprescription preparation include vitamin , mineral , phytotherapeutic/herbal/plantderived preparation , within 7 day prior initial Checkin Study Completion , unless deem acceptable Investigator 12. poor peripheral venous access 13. donation blood plasma within 8 week first dose administration Study Completion 14. receipt blood product within 2 month prior initial Checkin least 28 day follow last dose study drug 15. acute chronic condition , opinion Investigator , would limit subject 's ability complete and/or participate clinical study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>